## ABBV: AbbVie Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.42 indicates fundamental undervaluation. Quality metrics strong (ROE 138%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($213.92)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. iSAM Funds UK Ltd Takes $3.39 Million Position in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251209T140740 | Somewhat-Bullish | Relevance: 99%
-  iSAM Funds UK Ltd has initiated a new position in AbbVie Inc. (NYSE:ABBV), purchasing 18,267 shares valued at approximately $3.39 million. This investment accounts for 0.7% of the fund's portfolio, making AbbVie its 16th largest holding. AbbVie recently raised its quarterly dividend to $1.73 and reported robust Q3 earnings, surpassing analyst expectations with $1.86 EPS on $15.78 billion in revenue.

**2. Crohn’s Disease Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | AbbVie, Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH**
- Source: Barchart.com | 20251210T150741 | Bullish | Relevance: 99%
- The Crohn’s Disease market is projected to grow significantly, reaching approximately $10,777 million in 2024 and expanding with a 4.3% CAGR during 2020-2034, driven by increasing prevalence, awareness, and the launch of new pipeline products. Key market players like AbbVie, Merck, and Eli Lilly are developing advanced therapies, including biosimilars and IL-23 inhibitors, which are transforming treatment options and market dynamics, particularly in the US, Europe, and Japan. The report highlights several recent therapeutic approvals and advancements, demonstrating a robust pipeline for managing this chronic inflammatory condition.

**3. Scotiabank Sticks to Their Buy Rating for AbbVie (ABBV)**
- Source: The Globe and Mail | 20251211T124133 | Bullish | Relevance: 98%
- Scotiabank analyst Louise Chen has reiterated a Buy rating for AbbVie (ABBV) with a price target of $280.00. This follows AbbVie's recent Q3 earnings report, which showed $15.78 billion in revenue. Other analysts have offered mixed ratings, with HSBC issuing a Buy and TR | OpenAI – 4o maintaining a Hold.

**4. HSBC Upgrades AbbVie (ABBV) to Buy, Raises Price Target to $265 | ABBV Stock News**
- Source: GuruFocus | 20251210T123815 | Bullish | Relevance: 98%
- HSBC has upgraded AbbVie (ABBV) from Hold to Buy, increasing its price target by 17.78% to $265. This upgrade reflects HSBC's confidence in AbbVie's future growth potential, driven by strategic developments and recent acquisitions. Other analysts also maintain largely positive ratings for the pharmaceutical firm.

**5. HSBC Upgrades AbbVie to Buy From Hold, Adjusts Price Target to $265 From $225**
- Source: marketscreener.com | 20251210T104529 | Bullish | Relevance: 98%
- HSBC has upgraded its rating for AbbVie Inc. (NYSE: ABBV) from "Hold" to "Buy" and increased its price target to $265 from $225. The upgrade reflects a positive outlook on the biopharmaceutical company's future performance and valuation. This decision by HSBC signals increased confidence in AbbVie's stock for investors.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | HSBC | $265 | $225 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | HSBC | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($0.06M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.1% (+0.2%)
- Blackrock Inc.: 8.3% (-1.0%)
- JPMORGAN CHASE & CO: 6.4% (+97.6%)
- State Street Corpora: 4.5% (-0.2%)
- Morgan Stanley: 2.4% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.42 indicates undervaluation relative to growth. Forward P/E 15.7x attractive for 34% earnings growth. Quality metrics strong (ROE 138%). Balance sheet: $6.5B free cash flow. Analyst sentiment positive (1 raises, avg +18%). Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $395.9B |
| Beta | 0.35 |
| 52W Range | $164.39 - $244.81 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.42 |
| Forward P/E | 15.7 |
| Current P/E | 21.0 |
| YoY Growth | 33.9% |
| EPS Direction | FALLING |

### Technicals

MRS_20 weakening modestly (-0.8% over 5 days). Below STRENGTH zone by 8.3pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). MACD histogram bearish (-0.77), momentum weakening. RSI neutral at 46.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.28% (CS: 15) | Weak |
| RSI_14 | 45.8 | Neutral |
| MACD Histogram | -0.77 | Bearish |
| vs SMA20 | 0.979x | Below |
| vs SMA50 | 0.984x | Below |
| vs SMA200 | 1.092x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $223.98
- **Stop Loss:** $213.92 (4.5% risk)
- **Target:** $244.10 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 137
- **Position Value:** $30,685.26
- **Portfolio %:** 30.69%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-06 (Est: $3.35)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.86 | +4.2% |
| 2025Q2 | $2.91 | $2.97 | +2.1% |
| 2025Q1 | $2.40 | $2.46 | +2.6% |
| 2024Q4 | $2.12 | $2.16 | +1.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*